These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 14671500)

  • 1. Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance.
    Dunbar LM
    Am J Med Sci; 2003 Dec; 326(6):360-8. PubMed ID: 14671500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of new antibacterial therapies in at-risk populations.
    Lorenz J
    J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D; Zhanel G; Hoban D
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM; Dever LL
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiology of newer fluoroquinolones: focus on respiratory pathogens.
    Jones RN
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):213-20. PubMed ID: 12493166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibiotic resistance: infections of the upper respiratory tract and bronchi. When are antibiotics necessary?].
    Zellweger C; Täuber MG
    Ther Umsch; 2002 Jan; 59(1):21-9. PubMed ID: 11851042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.
    Hammerschlag MR; Roblin PM; Bébéar CM
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():25-31. PubMed ID: 11566973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
    Appelbaum PC
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012].
    Zhao C; Zhang F; Wang Z; Cao B; Xu X; Sun H; Zhang R; Hu Y; Liu Z; Du Y; Chen R; Zhuo C; Su D; Liu Y; Hu B; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2015 Jan; 38(1):18-22. PubMed ID: 25791651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ketolides: a critical review.
    Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
    Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.
    Stratton CW
    Emerg Infect Dis; 2003 Jan; 9(1):10-6. PubMed ID: 12533275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of upper respiratory tract infections in the primary care setting.
    Fendrick AM; Saint S; Brook I; Jacobs MR; Pelton S; Sethi S
    Clin Ther; 2001 Oct; 23(10):1683-706. PubMed ID: 11726004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
    Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.